Search Results
53 Results Found for “Huntington’s disease”
We are delighted to announce Dr ​​Rebecca Casterton as a touchNEUROLOGY Future Leader 2026, selected by peers as one of the neurologists changing the future of neurodegenerative disease. We spoke with Dr Rebecca Casterton (University of Cape Town, Cape Town, South ...
It is my pleasure to introduce the 2025 of touchREVIEWS in Neurology, which brings together an exceptional collection of reviews, original research and congress highlights that reflect the continued evolution of neurological science and clinical innovation. This issue opens with Jelle ...
Huntington’s disease (HD) is a fatal, autosomal-dominant, neurodegenerative disorder caused by a cytosine–adenine–guanine (CAG) trinucleotide repeat expansion in the huntingtin (HTT) gene, located on chromosome 4p16.3. When this repeat exceeds 36 units, it leads to the synthesis of ...
The Phase 1/2 study of AMT-130, the first in-human gene therapy designed to slow the course of Huntington’s disease (HD), has announced positive topline results from its pivotal trial.1 The data provide hope that a intrastriatal adeno-associated virus (AVV)-based ...
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of upper and lower motor neurons that results in progressive motor impairment. ALS is the most common disease of motor neurons with an annual incidence of approximately 1.7–2.5 per 100,000 people. It is a ...
Brain Awareness Week, taking place from March 10-16, 2025, is a global campaign dedicated to fostering public enthusiasm and support for brain science, organised by the Dana Foundation. Each March, participants worldwide organize imaginative activities that highlight the wonders of the brain and the profound impact of neuroscience on our daily lives.
Huntington’s disease (HD) is a neurodegenerative disease inherited in an autosomal dominant manner. It is caused by an expansion of cytosine, adenine, guanine (CAG) repeats within the huntingtin (HTT) gene, which is located on chromosome 4. This pathological expansion of ...
Explore ground-breaking advancements in the treatment of movement disorders in this insightful interview with Prof. K. Ray Chaudhuri, who shares his key takeaways from the 10th Congress of the European Academy of Neurology meeting in Helsinki. He discusses promising new therapies, personalized care approaches, and significant research on the staging of Parkinson's. Additionally, Prof. Chaudhuri emphasizes the importance of holistic treatment, stepped-care strategies, remote management, and the potential of wearable technology in improving patient outcomes, bringing his wealth of knowledge and insights to touchNEUROLOGY
Key highlights from the 10th Congress of the European Academy of Neurology (EAN) in Helsinki (EAN2024).
In the latest edition of touchREVIEWS in Neurology, we are pleased to present a collection of insightful articles that highlight the current landscape and future directions in neurological research and treatment. Firstly, Rajvinder Karda opens this issue with a compelling ...
Huntington’s disease (HD) is a genetic neurodegenerative disease that can affect movement, cognition and mental health. It is caused by a dominant mutation in the huntingtin gene, HTT. HD is estimated to occur in 5–10 people per 100,000 yearly, worldwide.1 Pridopidine (...
The phase 2 study results of ANX005, a humanized monoclonal antibody targeting C1q, for patients with Huntington’s disease were presented at MDS 2022. In this touchNEUROLOGY interview, we speak with Dr Rajeev Kumar (Rocky Mountain Movement Disorders Center, Englewood, CO, ...
ANX005, a humanized monoclonal antibody, is designed to inhibit the classical complement pathway which has been associated with Huntington’s disease (HD). In this touchNEUROLOGY interview, we speak with Dr Rajeev Kumar (Rocky Mountain Movement Disorders Center, Englewood, CO, USA) ...
This study in patients with Huntington's disease aimed to assess insulin-like growth factor-1 (IGF-1) levels and hypothalamic function, and the association with non-motor symptoms and brain structure. In this touchNEUROLOGY interview, we speak with Dr Esther Cubo (Hospital Universitario de ...
Huntingtin (HTT) is a gene containing a key region of CAG repeats. Dr Salvatore Mazzeo (University of Florence, Florence, Italy) discusses his study on HTT alleles containing from 27 to 35 CAG repeats – termed intermediate alleles (IAs) – and the effect of these ...
In this touchNEUROLOGY interview at EAN 2022, Dr Salvatore Mazzeo (University of Florence, Florence, Italy) discusses his study on HTT alleles containing from 27 to 35 CAG repeats – termed intermediate alleles (IAs) – and the effect of these IAs on progression of cognitive impairment ...
There are currently no disease-modifying medications for the treatment of Huntington's disease, and current treatment is entirely dependent on symptomatic therapies. Prof. Erin Furr-Stimming (McGovern Medical School, University of Texas, Health Science Centre, Houston, TX, USA) joins touchNEUROLOGY to discuss ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
